Monday, March 16, 2026

Cold Truth: How Air Conditioning Can Harm Your Health

The number of patients suffering from air conditioning sickness is predicted to increase significantly.

Hyundai Ioniq 5 N TA Spec Breaks Tsukuba Circuit Record by Over 2 Seconds

Hyundai N's Ioniq 5 N TA Spec sets a new record in Japan, outperforming Tesla with a lap time of 57.446 seconds.

North Korea Reports Mining, Chemical, and Agricultural Gains as Workers’ Party Marks 80 Years

North Korea celebrates the Workers' Party's 80th anniversary with economic achievements, loyalty letters, and cultural activities for seniors.

Jung Eun Kim

Author's Latest

Huons BioPharma’s Botulinum Toxin HUTOX Set to Transform the Chinese Market

Huons BioPharma partners with iMaker Technology to supply botulinum toxin, aiming for a strong market presence in China.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

Alteogen Secures U.S. Patent for Keytruda Subcutaneous Injection: What This Means for ALT-B4 and Future Treatments

Alteogen secures a U.S. patent for a subcutaneous Keytruda formulation using ALT-B4, ensuring exclusivity until 2043 and potential $1B in sales.

Samsung Biologics Partners with Eli Lilly: How This Open Innovation Hub Will Transform K-Bio by 2027

Samsung Biologics partners with Eli Lilly to create a biotech innovation hub in Korea, enhancing growth opportunities for local firms.

South Korea’s Pharmaceutical Future: 500 Million USD Investment from Eli Lilly to Boost K-Bio Innovation

South Korea partners with Eli Lilly to boost biotech and pharma industries, investing $500M to enhance innovation and healthcare access.

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

Ubicare Targets 80%+ Operating Profit Growth in 2026 — Here’s What’s Changing in Its EMR and Platform Play

Ubicare reported a 46% increase in operating profit for 2025, driven by optimized revenue structures and plans for AI solutions in 2026.

How Lunit’s AI is Transforming Early Breast Cancer Risk Assessment: Key Findings from ECR 2026

Lunit presents 21 research findings at ECR 2026, showcasing AI's potential in breast cancer risk assessment and screening innovations.

A New Adult Pneumococcal Shot Hits Korea: 21-Valent Coverage Targeting 80% of Adult Invasive Cases

Korean MSD launches Capvaxive, a 21-valent vaccine for adults to prevent pneumococcal diseases, targeting high-risk populations.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Korean Health Insurance Corporation Wins Platinum Award for Sustainability Report: What This Means for ESG Practices

NHIS wins Platinum Award at LACP Vision Awards for its sustainability report, achieving a perfect score in seven categories.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Korea’s Olive Young Gets a New Sleep Aid: Daewon Launches Honey Sleep Shot Backed by a Study

Daewon Health launches Honey Sleep Shot, a plant-based sleep aid, in 900 Olive Young stores, targeting sleep issues for modern consumers.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.